The Department of Biopharmacy works on projects on the development of several new drugs such as luteinizing hormone-releasing hormone (LH-RH) analogs, somatostatin analogs, bombesin/gastrin-releasing peptide (GRP) antagonists, targeted cytotoxic peptide analogs and growth hormone-releasing hormone (GH-RH) antagonists for the treatment of human cancers such as breast cancer, prostate cancer, ovarian carcinoma, pancreatic cancer, lunger cancer, colon cancer and the other tumours. Our research work demonstrated the presence of receptors and the expression of their mRNA for bombesin/GRP, LH-RH, somatostatin and GH-RH in various human cancers as new molecular targets, which is a very exciting development in cancer research, as it may lead to new methods for the diagnosis and treatment of such malignancies. We also investigate the mechanism of action of peptide analogs and targeted cytotoxic peptide conjugates on human cancer models and our team studies the down regulation, subcellular distribution, internalization and translocation of peptide and growth factor receptors in human cancers.